Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.48 |
| ▸ | KDR | P35968 | 7/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 4/20 | 0.43 |
| ▸ | BCR | P11274 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5787306 | 0.89 | TGFBR1 (0.45) | TGFBR1KDRMAPK14ABL1BCR | |
| SCHEMBL5787871 | 0.88 | TGFBR1 (0.50) | TGFBR1KDRMAPK14HPGDABL1 | |
| SCHEMBL5789274 | 0.84 | TGFBR1 (0.46) | TGFBR1KDRMAPK14JAK2JAK1 | |
| SCHEMBL5788683 | 0.82 | USP7 (0.48) | TGFBR1KDRMAPK14 | |
| SCHEMBL5789604 | 0.79 | TGFBR1 (0.43) | TGFBR1KDRMAPK14 | |
| SCHEMBL5791586 | 0.79 | TGFBR1 (0.59) | TGFBR1KDRMAPK14 | |
| SCHEMBL5907496 | 0.78 | TGFBR1 (0.56) | TGFBR1KDRMAPK14HPGDABL1 | |
| SCHEMBL5802786 | 0.78 | TGFBR1 (0.50) | TGFBR1HPGDABL1BCRMKNK1 | |
| SCHEMBL5790314 | 0.78 | TGFBR1 (0.46) | TGFBR1KDRMAPK14 | |
| SCHEMBL5790966 | 0.77 | TGFBR1 (0.44) | TGFBR1KDRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1543003-B1 | IMIDAZO¬1,2-A|PYRIDINES | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050234029-A1 | Compounds | DODIC NERINA | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234029-A1 | Compounds | SMAD3, SMAD2, ACVR1 | TGFBR1 4/4885KDR 160/4885MAPK14 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.